EDIT Stock — Editas Medicine Inc.: Cash, EV, Pipeline

Share price

$2.70

Market cap

$414.7M

Cash

$211.6M

Enterprise value

$251.3M

Balance sheet

Cash	$211.6M
Debt	$48.2M
Net cash	$163.4M
Enterprise value	$251.3M
Basic shares	97.9M shares
Fully diluted shares	221.9M shares
Fully diluted market cap	$599.0M
Cash per share	$2.16

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading EDIT daily closes…

Loading price history…

Pipeline assets

EDIT-401

Preclinical · Active Modality: In vivo gene editing (LNP-delivered)

Target HBG1/2 promoter (gamma-globin)

Indications

Sickle cell disease / transfusion-dependent beta thalassemia (hemoglobinopathies) (Preclinical)

Status note Lead program: in vivo gene editing for hemoglobinopathies; company focusing resources on advancing to human proof-of-concept.

renizgamglogene autogedtemcel (reni-cel)

Stage not disclosed · Terminated Modality: Ex vivo gene-edited cell medicine (AsCas12a)

Target HBG1/HBG2 promoter (gamma-globin)

Indications

Sickle cell disease / transfusion-dependent beta thalassemia (Stage not disclosed)

Status note Dec 2024: board approved discontinuation of clinical development; company ceased activities toward BLA filing and potential commercialization to optimize cost structure and accelerate in vivo gene editing. Approximately 180 positions (65%) eliminated in associated restructuring.

CD19 HD Allo CAR T (BMS program)

Phase 1 · Active Modality: Allogeneic CAR T

Target CD19

Partnerships BMS (via Juno Therapeutics): collaboration and license; Editas provides Cas9/AsCas12a platform; BMS funds and owns development. One of 14 programs under the collaboration; Immatics non-exclusive gamma-delta T cell collaboration programs not named.

Indications

Autoimmune disease (Phase 1)

Status note BMS' program using Editas platform technology; one of 14 programs under the BMS collaboration. Other named programs: Immatics non-exclusive gamma-delta T cell collaboration (programs not named).

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EDIT-301
Lead indication	Sickle Cell Disease
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04853576	Phase 2	Active, not recruiting	Sponsor	EDIT	—	Sickle Cell Disease; Hemoglobinopathies	—
NCT05444894	Phase 2	Active, not recruiting	Sponsor	EDIT	—	Transfusion Dependent Beta Thalassemia; Hemoglobinopathies; Thalassemia Major	—
NCT06363760	Not disclosed	Enrolling by invitation	Sponsor	EDIT	—	Sickle Cell Disease; Transfusion-dependent Beta-Thalassemia; Hemoglobinopathies	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Editas Medicine, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	8,889,000	+8,889,000	1.35%	2026-08-14
Logos Global Management	2,222,000	+2,222,000	0.31%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

EDIT — Editas Medicine Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials

Institutional holders